...
首页> 外文期刊>Analytical chemistry >Identification of Differential Protein Binding Affinities in an Atropisomeric Pharmaceutical Compound by Noncovalent Mass Spectrometry, Equilibrium Dialysis, and Nuclear Magnetic Resonance
【24h】

Identification of Differential Protein Binding Affinities in an Atropisomeric Pharmaceutical Compound by Noncovalent Mass Spectrometry, Equilibrium Dialysis, and Nuclear Magnetic Resonance

机译:通过非共价质谱,平衡透析和核磁共振鉴定阻转异构药物化合物中的差异蛋白结合亲和力

获取原文
获取原文并翻译 | 示例
           

摘要

Atropisomerism of pharmaceutical compounds is a challenging area for drug discovery programs (Angew. Chem., Int. Ed. 2009, 48, 6398-6401). Strategies for dealing with these compounds include raising the energy barrier to atropisomerization in order to develop the drug as a single isomer (Tetrahedron 2004, 60, 4337-4347) or reducing the barrier to rotation and developing a mixture of rapidly interconverting isomers (Chirality 1996, 8, 364-371). Commonly, however, the atropisomers will be differentiated in terms of their affinity for a given protein target, and it is therefore important to rapidly identify the most active component prior to further compound development. We present equilibrium dialysis and saturation transfer difference NMR (STD-NMR) as techniques for assessing relative affinities of an atropisomeric mixture against antiapoptotic protein targets Bcl-2 and Bcl-x_L. These techniques require no prior separation of the mixture of compounds and are therefore rapid and simple approaches. We also explore the use of noncovalent mass spectrometry for determining K_D values of individual atropisomers separated from the equilibrium mixture and compare the results to solution-phase measurements. Results from equilibrium dialysis, STD-NMR, and noncovalent mass spectrometry are all in excellent agreement and provide complementary information on differential binding, amplification of the strongest binders, and K_D values.
机译:药物化合物的阻转异构性是药物发现计划的挑战性领域(Angew。Chem。,Int。Ed。2009,48,6398-6401)。处理这些化合物的策略包括提高对麻风异构化的能垒,以便将药物开发为单一异构体(Tetrahedron 2004,60,4337-4347)或减少旋转障碍并开发快速互变异构体的混合物(Chirality 1996) ,8,364-371)。然而,通常,阻转异构体将根据它们对给定蛋白质靶标的亲和力而有所区别,因此重要的是在进一步开发化合物之前迅速鉴定出最具活性的组分。我们目前的平衡透析和饱和转移差NMR(STD-NMR)作为评估抗凋亡蛋白靶标Bcl-2和Bcl-x_L的对映异构体混合物的相对亲和力的技术。这些技术不需要事先分离化合物的混合物,因此是快速而简单的方法。我们还探索了使用非共价质谱法确定从平衡混合物中分离出的单个阻转异构体的K_D值,并将结果与​​溶液相测量结果进行比较。平衡透析,STD-NMR和非共价质谱的结果都非常吻合,并提供了有关差分结合,最强结合剂的扩增和K_D值的补充信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号